Generation of a Cellular Model of CADASIL From Skin Fibroblasts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02032225|
Recruitment Status : Unknown
Verified December 2016 by Institut National de la Santé Et de la Recherche Médicale, France.
Recruitment status was: Enrolling by invitation
First Posted : January 9, 2014
Last Update Posted : December 7, 2016
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy (CADASIL) is an archetypal small vessel disease of the brain caused by dominant mutations in the NOTCH3 receptor. Cardinal vascular lesions include deposition of granular osmiophilic material (GOM) within the basal lamina of smooth muscle cells, progressive smooth muscle cell loss, and fibrosis of the media. Pathogenic mutations alter the number of cysteine residues in the extracellular domain of NOTCH3 (Notch3 ECD), leading to its abnormal accumulation in the GOM deposits. Vascular smooth muscle cell has been identified as the primary target cell in this disease. Pathophysiological processes leading from NOTCH3 mutations to smooth muscle cell loss remain poorly understood.
The investigators propose to study these mechanisms by reprogramming skin cells to become stem cells and then differentiating them to vascular smooth muscle cells.
The hypothesis of this study is that the differentiated smooth muscle cells will display the characteristic features of CADASIL, ie, Notch3 ECD accumulation and GOM deposits.
|Condition or disease||Intervention/treatment|
|CADASIL||Other: Skin biopsy|
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||Obtention d'un modèle Cellulaire de la Maladie CADASIL à Partir de Fibroblastes cutanés de Patients|
|Study Start Date :||February 2014|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2018|
patients with CADASIL
Other: Skin biopsy
- Derivation of iPS cells from skin biopsies of patients with CADASIL [ Time Frame: 30 months ]
- Differentiation of iPS cells to vascular smooth muscle cells, phenotypic and mechanistic analyses [ Time Frame: 24 mois ]Differentiation of iPS cells to vascular smooth muscle cells and phenotypic analysis (12 mois) Mechanistic analyses (12 mois)
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02032225
|Paris, France, 75010|
|Principal Investigator:||Anne JOUTEL, MD, PhD||Institut National de la Santé Et de la Recherche Médicale, France|